Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There hav...

Full description

Bibliographic Details
Main Authors: Max Holzer, Nico Schade, Ansgar Opitz, Isabel Hilbrich, Jens Stieler, Tim Vogel, Valentina Neukel, Moritz Oberstadt, Frank Totzke, Christoph Schächtele, Wolfgang Sippl, Andreas Hilgeroth
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/23/9/2335